Stocks · Healthcare · Biotechnology
Vor Biopharma Inc. VOR
$18.69 +3.49% Close, Oct 2, 2026 · NASDAQ · Market cap $1.01B
High risk
Next earnings report: Nov 12, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 767.0% in a year.
- Over the past year the stock returned -52.4%, behind the S&P 500 by 67.5 percentage points.
- The stock is in an uptrend: above its 200-day average for 68 trading days, with the 50-day average above the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 40%
- Cash conversion (OCF / net income)Bottom 4%
- Accruals (lower is better)Bottom 1%
- Net debt / EBITDA (lower is better)Top 30%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 1%
- Free-cash-flow yieldBottom 32%
- EBITDA / enterprise valueTop 1%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 11%
- 6-month returnBottom 46%
- 1-year return vs S&P 500Bottom 9%
- Distance from 52-week highBottom 21%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 30%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 50%
- Upside to consensus price targetBottom 47%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 31%
- Maximum drawdown, 3 yearsBottom 6%
- Beta vs S&P 500 (lower is better)Bottom 1%
- Net debt / EBITDA (lower is better)Top 30%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Return on invested capital | -32.2% | — | Bottom 40% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- -0.22×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 159.7%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -0.16×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -39.94%
- Shareholder yield
- -39.94%
- Share count change, 1 year
- +767.0%
- Share count change, 3-year CAGR
- +153.0%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 11, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 2 of 8
- Average EPS surprise, last 4
- +15.8%
- Average 2-day reaction, last 8
- -2.8%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $29.00
- Target vs current price
- +55.2%
- Analysts with a rating
- 13
- Share rating Buy or Strong Buy
- 77%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 11, 2026 | -68.1% | +0.9% | -1.5% | +7.4% | — |
| May 13, 2026 | +2.7% | -3.4% | -14.2% | -21.1% | +43.7% |
| Mar 30, 2026 | +4003.5% | +1.5% | +12.4% | -2.5% | +0.0% |
| Nov 13, 2025 | -3874.8% | -3.1% | -22.3% | +20.6% | +38.1% |
| Aug 12, 2025 | -2103.5% | -16.6% | +2.5% | +1.0% | -48.3% |
| May 15, 2025 | -4.0% | +0.0% | +6.7% | +21.1% | +1063.7% |
| Mar 20, 2025 | -2488.2% | +0.9% | -4.0% | -23.0% | -78.4% |
| Nov 7, 2024 | +0.0% | -3.0% | +11.5% | -1.7% | +69.8% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 11, 2026 | -$1.16 | -$0.69 | -68.1% | — |
| May 13, 2026 | -$0.73 | -$0.75 | +2.7% | — |
| Mar 30, 2026 | $44.50 | -$1.14 | +4003.5% | — |
| Nov 13, 2025 | -$121.63 | -$3.06 | -3874.8% | — |
| Aug 12, 2025 | -$251.20 | -$11.40 | -2103.5% | — |
| May 15, 2025 | -$5.20 | -$5.00 | -4.0% | — |
| Mar 20, 2025 | -$8.80 | -$0.34 | -2488.2% | — |
| Nov 7, 2024 | -$8.00 | -$8.00 | +0.0% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / EBITDA | 1.4× | — | — | Top 1% |
| Free-cash-flow yield | -13.93% | — | — | Bottom 32% |
| Earnings yield | -3150.45% | — | — | Bottom 1% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 68
- 50-day average slope (20 days)
- +4.7%
- 200-day average slope (20 days)
- +7.7%
- Distance from 50-day average
- -14.9%
- Distance from 200-day average
- +11.5%
- RSI (14)
- 37.6
- Relative volume
- 0.58×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 68.0%
- Volatility vs own 5-year history
- 11th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 5.02
- Correlation with S&P 500
- 0.27
- Current drawdown from 1-year high
- -50.1%
- Maximum drawdown, 3 years
- -94.7%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Feb 25, 2021 | May 9, 2025 | -99.7% | 1056 days | Not yet recovered |
| Feb 16, 2021 | Feb 23, 2021 | -16.8% | 5 days | 1 days (Feb 24, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $1.01B
- EPS, diluted (TTM)
- -$588.82
- Revenue (TTM)
- $0
- 52-week range
- $6.50 – $42.75
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | -$9.0M | -$3.5M | $0 | $0 |
| Operating income | -$69.0M | -$93.4M | -$126.0M | -$121.2M | -$371.6M |
| Net income | -$68.9M | -$92.1M | -$117.9M | -$116.9M | -$696.0M |
| EPS (diluted) | -$37.80 | -$46.60 | -$35.00 | -$34.00 | -$70.50 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$27.6M | -$30.7M | -$32.5M | -$1.57B | -$812.7M | $1.72B | -$219.6M | -$62.8M |
| EPS (diluted) | -$8.00 | -$9.00 | -$5.20 | -$251.20 | -$121.63 | $44.50 | -$510.53 | -$1.16 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$69.1M | -$85.1M | -$100.3M | -$99.7M | -$142.7M |
| Capital expenditure | -$3.9M | -$8.5M | -$1.1M | -$229,000 | -$941,000 |
| Free cash flow | -$73.0M | -$93.6M | -$101.4M | -$99.9M | -$143.7M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $189.2M | $116.0M | $4.6M | $55.8M | $505.1M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $466.1M
- Total assets
- $481.1M
- Total liabilities
- $681.3M
- Total debt
- $2.9M
- Net debt
- -$105.0M
- Shareholders’ equity
- -$200.2M
As of Jun 30, 2026 (filed Aug 11, 2026).
Short interest
- Shares sold short
- 7,904,520
- Days to cover
- 11.12
- Change vs previous report
- +3.1%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Sep 19, 2025
- 1-for-20